Skip to main content

Table 2 Cox proportional hazards model for disease-free and overall survivals of 254 patients with EOC

From: BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

DFS Univariate HR (95% CI)b p Multivariate HR (95% CI)b p OS Univariate HR (95% CI)b p Multivariate HR (95% CI)b p
FIGO stage [advanced/early] 3.6 (2.2–5.8) < 0.001 2.3 (1.3–4.2) 0.004 FIGO stage [advanced/early] 2.6 (1.3–4.8) 0.004 1.3 (0.6–2.7) 0.53
Histology [serous/non-serousa] 1.5 (1.1–2.2) 0.01 1.1 (0.8–1.6) 0.63 Histology [serous/non-serousa] 1.1 (0.7–1.7) 0.74   
Tumor grade [3/1–2] 2.0 (1.1–3.4) 0.015 1.6 (0.9–2.8) 0.11 Tumor grade [3/1–2] 1.4 (0.7–2.9) 0.39   
Postoperative residual tumor [≥1 cm/< 1 cm] 2.8 (2.1–3.9) < 0.001 2.1 (1.4–2.9) < 0.001 Postoperative residual tumor [> 1 cm/<  1 cm] 3.1 (2.0–5.0) < 0.001 2.7 (1.6–4.7) < 0.001
BTLA expression [detectable/non- detectable] 2.0 (1.4–2.9) < 0.001 1.7 (1.2–2.4) 0.002 BTLA expression [detectable/non- detectable] 2.0 (1.2–3.5) 0.009 1.8 (1.04–3.0) 0.035
  1. Abbreviations: EOC epithelial ovarian carcinoma; DFS disease-free survival; OS overall survival; HR Hazard ratio; CI confidence interval; FIGO International Federation of Gynecology and Obstetrics; BTLA B and T lymphocyte attenuator
  2. aNon-serous includes mucinous, clear cell, endometrioid, and undifferentiated types
  3. bCox regression model